• OPEN AN ACCOUNT
Indian Indices
Sensex
81,909.63 -270.84
( -0.33%)
Global Indices
Nasdaq
49,100.54 590.94
(1.22%)
Dow Jones
6,896.35 78.48
(1.15%)
Hang Seng
52,693.20 -297.90
(-0.56%)
Nikkei 225
10,155.70 28.92
(0.29%)
Forex
USD-INR
90.86 0.32
(0.35%)
EUR-INR
105.69 0.68
(0.65%)
GBP-INR
121.83 0.75
(0.62%)
JPY-INR
0.58 0.00
(0.45%)

EQUITY - MARKET SCREENER

Espire Hospitality Ltd
Industry :  Hotels
BSE Code
ISIN Demat
Book Value()
532016
INE176O01011
26.2584007
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
147.26
441.71
EPS(TTM)
Face Value()
Div & Yield %
2.01
10
0
 

hazoor multi projects ltd
Astrazeneca Pharma and Sun Pharma form second brand partnership
Nov 17,2025
Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma® whereas Sun Pharma will promote and distribute the therapy as Gimliand®. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.